Beranda › Mieloma Multipel › New York › Queens
Uji klinis Mieloma Multipel di Queens, NY
20 studi untuk Mieloma Multipel mencari peserta di lokasi sekitar Queens (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Menerima pesertaFase 2
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale · 13 mi jauhnya
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Menerima pesertaFase 3
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola · 11 mi jauhnya
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Menerima pesertaFase 3
- NYU Winthrop, Mineola · 11 mi jauhnya
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Menerima pesertaFase 3
- Northwell Health Cancer Institute, Lake Success · 9 mi jauhnya
- NYU Langone Hospital Long Island, Mineola · 11 mi jauhnya
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Menerima pesertaFase 3
- MSK Nassau, Uniondale · 13 mi jauhnya
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Menerima pesertaFase 2
- Queens Cancer Center, Rego Park · 3 mi jauhnya
- Cohen Children's Medical Center, New Hyde Park · 9 mi jauhnya
- Northwell Health Monter Cancer Center, Lake Success · 9 mi jauhnya
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
Menerima pesertaFase 2
- Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale · 13 mi jauhnya
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Menerima pesertaFase 3
- Long Island Jewish Medical Center, New Hyde Park · 9 mi jauhnya
- Northwell Health/ RJ Zuckerberg Cancer Center, Lake Success · 9 mi jauhnya
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Menerima pesertaFase 3
- MSK Nassau, Uniondale · 13 mi jauhnya
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
Menerima pesertaFase 1
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale · 13 mi jauhnya
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Menerima pesertaFase 3
- Research Site, New Hyde Park · 9 mi jauhnya
A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
Menerima pesertaStudi observasional
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Rockville Centre · 10 mi jauhnya
A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
Menerima pesertaFase 1/2
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale · 13 mi jauhnya
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Menerima pesertaFase 2
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale · 13 mi jauhnya
A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
Menerima pesertaFase 2
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale · 13 mi jauhnya
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Menerima pesertaFase 1/2
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola · 11 mi jauhnya
A Dietary Study for People With Multiple Myeloma
Menerima peserta
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale · 13 mi jauhnya
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Menerima pesertaFase 2
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale · 13 mi jauhnya
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Memorial Sloan Kettering Rockville, Rockville Centre · 10 mi jauhnya
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Menerima peserta
- Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale · 13 mi jauhnya
Uji klinis Mieloma Multipel di kota lain
- New York City, NY60 studi
- Boston, MA42 studi
- Atlanta, GA41 studi
- Houston, TX38 studi
- Durham, NC37 studi
- Nashville, TN32 studi
- Denver, CO27 studi
- Rochester, MN24 studi
- St. Louis, MO24 studi
- Columbus, OH24 studi
- Baldwin Park, CA23 studi
- Chicago, IL22 studi
Studi lain di Queens
- Kanker Payudara63 studi
- Kanker Paru Non-Sel Kecil49 studi
- Kanker Kolorektal31 studi
- Kanker Metastatik28 studi
- Kanker Ovarium28 studi
- Kanker Prostat27 studi
- Kanker (semua jenis)26 studi
- Kanker Endometrium25 studi
- Kanker Paru22 studi
- Leukemia Mieloid Akut21 studi
- Karsinoma Sel Skuamosa Kepala dan Leher20 studi
- Kanker Pankreas20 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.